Immuno-Oncology | Specialty

Pancreatic Cancer: Looking Beyond Second-Line Therapy

February 27th 2018

Immunotherapy in MSI-High Pancreatic Tumors

February 27th 2018

Second-Line Decision-Making in Pancreatic Cancer

February 27th 2018

Impact of Second-Line Approval of Liposomal Irinotecan

February 27th 2018

Pancreatic Cancer: Data With Liposomal Irinotecan/5-FU

February 27th 2018

Dosing Options With Nab-Paclitaxel/Gemcitabine

February 27th 2018

Sequencing Strategies in Pancreatic Cancer

February 27th 2018

Choosing Frontline Therapy in Metastatic Disease

February 27th 2018

Recent Advances in Pancreatic Cancer Research

February 27th 2018

Hepatocellular Carcinoma: Future Role of Immunotherapy

February 27th 2018

Optimizing Checkpoint Inhibitor Combinations in HCC

February 27th 2018

KEYNOTE-224: Improving HCC Outcomes With Pembrolizumab

February 27th 2018

Hepatocellular Carcinoma: Recent Approval of Nivolumab

February 27th 2018

Hepatocellular Carcinoma: Immunotherapy After Sorafenib

February 27th 2018

Recent Advances in the Treatment of Liver Cancer

February 27th 2018

Interventional Radiology and More for HCC

February 23rd 2018

Locoregional Therapies for Extrahepatic HCC

February 23rd 2018

Managing Locoregional Therapies in HCC

February 23rd 2018

Growing Treatment Landscape in Liver Cancer

February 23rd 2018

Novel Combinations on the Horizon in HCC

February 23rd 2018